Anthera Pharmaceuticals Inc. (ANTH) is a biopharmaceutical company having two product candidates in development - Sollpura for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and Blisibimod for the potential treatment of systemic lupus erythematosus and IgA nephropathy.A phase III study of Sollpura for the treatment of exocrine pancreatic insufficiency is underway. The top-line results from this study, known by the name SOLUTION, are expected this month.ANTH has lost more than 68% of its stock price so far this year, and trades around $1.47.